Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Feb 2024

Choi Yong June, Choi Munkyung, Park Jaewoo, Park Miso, Kim Myung Jun, Lee Jae-Sun, Oh Su-Jin, Lee Young Joo, Shim Wan Seob, Kim Ji Won, Kim Myung Jin, Kim Yong-Chul, Kang Keon Wook

Abstract excerpt

Lung cancer represents a significant global health concern and stands as the leading cause of cancer-related mortality worldwide. The identification of specific genomic alterations such as EGFR and KRAS in lung cancer has paved the way for the development of targeted therapies. While targeted therapies for lung cancer exhibiting EGFR, MET and ALK mutations have been well-established, the options for RET mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Source

Identifiers

PMID: 38198957
DOI: 10.1016/j.biopha.2024.116124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer.PMID 38198957Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

Treatment of non–small cell lung cancer with RET rearrangementsSemantic proximity Read ↗

Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.Semantic proximity Read ↗

<i><scp>RET</scp></i> fusion gene: Translation to personalized lung cancer therapySemantic proximity Read ↗

Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.Semantic proximity Read ↗

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Semantic proximity Read ↗

WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.Semantic proximity Read ↗

Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategiesSemantic proximity Read ↗

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cellsSemantic proximity Read ↗

Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.Semantic proximity Read ↗

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathwaySemantic proximity Read ↗

Anti-tumor activity of motesanib in a medullary thyroid cancer model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.